Biosynex SA
PAR:ALBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biosynex SA
Revenue
Biosynex SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biosynex SA
PAR:ALBIO
|
Revenue
€98m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
10%
|
CAGR 10-Years
34%
|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Revenue
€70.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Biomerieux SA
PAR:BIM
|
Revenue
€4.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
S
|
SMAIO SA
PAR:ALSMA
|
Revenue
€5.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Revenue
€108.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Mauna Kea Technologies SA
PAR:ALMKT
|
Revenue
€7.5m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-4%
|
|
Biosynex SA
Glance View
Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
See Also
What is Biosynex SA's Revenue?
Revenue
98m
EUR
Based on the financial report for Jun 30, 2025, Biosynex SA's Revenue amounts to 98m EUR.
What is Biosynex SA's Revenue growth rate?
Revenue CAGR 10Y
34%
Over the last year, the Revenue growth was -6%. The average annual Revenue growth rates for Biosynex SA have been -31% over the past three years , 10% over the past five years , and 34% over the past ten years .
